MAP6 and synucleinopathy: Interestingly, pathogenic α-synuclein disrupts MAP6 S-acylation and pharmacological inhibition of APT1 increases MAP6 S-acylation and protects against α-synuclein-dependent neurotoxicity, providing an interesting mechanistic link between S-acylation and altered α-synuclein-dependent vesicular transport that is characteristic of synucleinopathies such as PD (Ho et al, 2020).